Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers

Abnormal expression of activating/inhibitory receptors leads to natural killer (NK) cells dysfunction in tumor. Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumor-infiltrating NK cells from patients with digestive cancers including esophageal, liver, colorectal, gastric and biliary cancer. The increased PD-1 expression on NK cells indicates poorer survival in esophageal and liver cancers. Blocking PD-1/PD-L1 signaling markedly enhances cytokines production and degranulation and suppresses apoptosis of NK cells in vitro. PD-1/PD-L1 exerts inhibitory effect through repressing the activation of PI3K/AKT signaling in NK cells. More importantly, a PD-1 blocking antibody was found to significantly suppress the growth of xenografts in nude mice, and this inhibition of tumor growth was completely abrogated by NK depletion. These findings strongly suggested that PD-1 is an inhibitory regulator of NK cells in digestive cancers. PD-1 blockade might be an efficient strategy in NK cell-based tumor immunotherapy.

[1]  H. Dockrell,et al.  PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment , 2015, PloS one.

[2]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[3]  A. Pera,et al.  Immunosenescence: limitations of natural killer cell-based cancer immunotherapy , 2017, Cancer Immunology, Immunotherapy.

[4]  W. Pan,et al.  Monocyte/macrophage‐elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions , 2013, Hepatology.

[5]  A. Fauci,et al.  The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.

[6]  W. Mao,et al.  Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma , 2016, Oncotarget.

[7]  Xiang Gao,et al.  Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. , 2013, The Journal of clinical investigation.

[8]  C. Macedo,et al.  Decreased NKp46 and NKG2D and elevated PD‐1 are associated with altered NK‐cell function in pediatric transplant patients with PTLD , 2012, European journal of immunology.

[9]  Yan Chen,et al.  Human fused NKG2D–IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells , 2015, Cellular and Molecular Immunology.

[10]  Jingting Jiang,et al.  PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor , 2016, Clinical Cancer Research.

[11]  Jiri Polivka,et al.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.

[12]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[13]  R. Issels,et al.  Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients , 2016, Oncoimmunology.

[14]  D. Olive,et al.  Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization , 2017, The Journal of allergy and clinical immunology.

[15]  A. Kamphorst,et al.  Manipulating the PD-1 pathway to improve immunity. , 2013, Current opinion in immunology.

[16]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[17]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[18]  Jun Du,et al.  Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+ T-Cell Functions in Esophageal Squamous Cell Carcinoma , 2011, Clinical & developmental immunology.

[19]  W. Chua,et al.  The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. , 2016, Clinical colorectal cancer.

[20]  Abdus S. Wahed,et al.  Cutting Edge: Programmed Death-1 Expression Is Increased on Immunocytes in Chronic Hepatitis C Virus and Predicts Failure of Response to Antiviral Therapy: Race-Dependent Differences12 , 2008, The Journal of Immunology.

[21]  J. Riley PD‐1 signaling in primary T cells , 2009, Immunological reviews.

[22]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[23]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[24]  G. Dranoff,et al.  Dual roles for immunity in gastrointestinal cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[26]  J. Berzofsky,et al.  Lack of the programmed death‐1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules , 2016, Journal of leukocyte biology.

[27]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[28]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[29]  G. Giannelli,et al.  Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment , 2014, Gut.

[30]  Adam Coleman,et al.  PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. , 2012, Viral immunology.

[31]  Hongxin Ma,et al.  Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages , 2015, Gut.

[32]  Seung-Hwan Lee,et al.  IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells , 2015, Front. Immunol..

[33]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[34]  H. Fujii,et al.  NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[35]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[36]  Adam J. Bass,et al.  The Tumor Microenvironment in Esophageal Cancer , 2016, Oncogene.

[37]  Xinxiang Li,et al.  Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer , 2016, Molecular Cancer.

[38]  Y. Mohri,et al.  Role of inflammation and tumor microenvironment in the development of gastrointestinal cancers: what induced pluripotent stem cells can do? , 2015, Current Stem Cell Research & Therapy.

[39]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[40]  Yuzhang Wu,et al.  Programmed Death (PD)-1-Deficient Mice Are Extremely Sensitive to Murine Hepatitis Virus Strain-3 (MHV-3) Infection , 2011, PLoS pathogens.

[41]  J. Wargo,et al.  Monitoring immune responses in the tumor microenvironment. , 2016, Current opinion in immunology.

[42]  T. Osaki,et al.  Increased PD‐1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer , 2013, Journal of surgical oncology.

[43]  Song Han,et al.  The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells , 2015, PloS one.

[44]  D. Olive,et al.  PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma , 2016, Oncotarget.

[45]  K. Patel,et al.  Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability , 2016, The American journal of surgical pathology.

[46]  Laura F. Dagley,et al.  CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.

[47]  X. Lu,et al.  Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma , 2012, Hepatology.

[48]  J. Larrubia,et al.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. , 2016, World journal of gastroenterology.